PIQ — Proteomics International Laboratories Share Price
0.000.00%
Last trade - 00:00- AU$133.34m
- AU$128.30m
- AU$1.47m
- 42
- 10
- 79
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 24.92 | ||
| Price to Tang. Book | 24.92 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 92.28 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -104.31% | ||
| Return on Equity | -94.37% | ||
| Operating Margin | -415.31% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 1.52 | 1.61 | 1.47 | 1.72 | 1.47 | n/a | n/a | 4.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bio-analytical services. The Company specializes in proteomics, the study of the structure and function of proteins. The Company focuses on developing and commercializing diagnostic tests for chronic diseases. The Company operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. The PromarkerD test system is a blood test that assess the risk of diabetic kidney disease (DKD) in patients with type 2 diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Its Analytical Services includes a proteomics-based technology platform, used to test, and validate the protein composition of varied range of products.
Directors
- Terry Sweet NEC
- Jacqueline Gray CFO
- Richard Lipscombe MDR
- Vik Malik OTH
- Karen Logan SEC
- Paul Edward House NED
- Ian Moore NED
- Robyn Elliott NID (52)
- Neville Gardiner NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 9th, 2014
- Public Since
- April 16th, 2015
- No. of Shareholders
- 2,371
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 122,334,721
- Address
- Harry Perkins Institute, 6 Verdun Street, NEDLANDS, 6009
- Web
- https://www.proteomics.com.au/
- Phone
- +61 893891992
- Auditors
- BDO Audit (WA) PTY LTD
Upcoming Events for PIQ
Similar to PIQ
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Proteomics International Laboratories share price?
As of Today at 19:17 UTC, shares in Proteomics International Laboratories are trading at AU$1.09. This share price information is delayed by 15 minutes.
How has the Proteomics International Laboratories share price performed this year?
Shares in Proteomics International Laboratories last closed at AU$1.09 and the price had moved by +19.78% over the past 365 days. In terms of relative price strength the Proteomics International Laboratories share price has outperformed the ASX All Ordinaries Index by +14.57% over the past year.
What are the analyst and broker recommendations for Proteomics International Laboratories?
The overall consensus recommendation for Proteomics International Laboratories is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Proteomics International Laboratories dividend yield?
Proteomics International Laboratories does not currently pay a dividend.
Does Proteomics International Laboratories pay a dividend?
Proteomics International Laboratories does not currently pay a dividend.
When does Proteomics International Laboratories next pay dividends?
Proteomics International Laboratories does not currently pay a dividend.
How do I buy Proteomics International Laboratories shares?
To buy shares in Proteomics International Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Proteomics International Laboratories?
As of the previous close price of AU$1.09, shares in Proteomics International Laboratories had a market capitalisation of AU$133.34m.
Where are Proteomics International Laboratories shares listed?
Here are the trading details for Proteomics International Laboratories:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PIQ
What kind of share is Proteomics International Laboratories?
Based on an overall assessment of its quality, value and momentum Proteomics International Laboratories is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Proteomics International Laboratories share price forecast for 2024?
The analyst consensus target price for shares in Proteomics International Laboratories is AU$1.38. That is 26.61% above the last closing price of AU$1.09.
Analysts covering Proteomics International Laboratories currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.06 for the next financial year.
What is the trend in the Proteomics International Laboratories share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Proteomics International Laboratories. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +7.19%.
As of the last closing price of AU$1.09, shares in Proteomics International Laboratories were trading +15.93% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Proteomics International Laboratories PE Ratio?
The Proteomics International Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$1.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Proteomics International Laboratories?
Proteomics International Laboratories' management team is headed by:
- Terry Sweet - NEC
- Jacqueline Gray - CFO
- Richard Lipscombe - MDR
- Vik Malik - OTH
- Karen Logan - SEC
- Paul Edward House - NED
- Ian Moore - NED
- Robyn Elliott - NID
- Neville Gardiner - NID